4593: Healios K.K. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Healios K.K.

TYO:4593

SummaryFactSheetFinancial
Price
¥335.00
Loss Chance
57.9%
1.81JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Biotechnology
12 / 25
Health Care
143 / 184
Japan
?
2,903 / 3,513
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
GNI Group Ltd.
TYO:2160
3.32
¥2,955.00
100.00%
Heartseed
TYO:219A
2.10
¥1,783.00
> 1,000%
Transgenic Group
TYO:2342
2.52
¥248.00
100.00%
Pharma Foods International Co., Ltd.
TYO:2929
4.79
¥650.00
100.00%
AnGes
TYO:4563
2.60
¥50.00
100.00%
Jitta Factors
Growth Opportunity (34)
Recent Business Performance (8)
Financial Strength (24)
Return to Shareholders (0)
Competitive Advantage (32)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.81
100.00%
2.16
172.04%
4.36
368.05%
Biotechnology
3.32
100.00%
2.10
> 1,000%
2.52
100.00%
COMPANY DESCRIPTION
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
www.healios.co.jp
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.